MoonLake Immunotherapeutics - Class A —— 季度财务数据 (NASDAQ:MLTX) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

经营活动产生的现金 -48.47 M-38.14 M-54.53 M-44.54 M-58.79 M -196.01 M 投资活动产生的现金 -147.33 M56.25 M88.25 M88.4 M-29.91 M 202.99 M 融资活动产生的现金 150.71 K73.12 M0480 K72.39 M 146 M 自由现金流 -48.65 M-38.17 M-54.53 M-44.54 M-58.79 M -196.04 M

新闻

Clear Street上调Moonlake目标价,看好IL-17数据

Clear Street raises Moonlake stock price target on IL-17 data

Cantor Fitzgerald重申Moonlake股票评级,看好强直性脊柱炎市场潜力

Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential

H.C. Wainwright基于试验结果将Moonlake Immunotherapeutics目标价上调至40美元

Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake股价因axSpA试验数据积极而飙升

MoonLake stock surges on positive axSpA trial data

InvestingPro公允价值预测后MoonLake股价飙升63%